Bolthouse Investments LLC Purchases New Shares in Eli Lilly and Company (NYSE:LLY)

Bolthouse Investments LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, Holdings Channel reports. The firm acquired 700 shares of the company’s stock, valued at approximately $540,000.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Boothbay Fund Management LLC lifted its holdings in Eli Lilly and Company by 135.3% in the fourth quarter. Boothbay Fund Management LLC now owns 5,457 shares of the company’s stock worth $4,213,000 after buying an additional 3,138 shares during the period. Virtus ETF Advisers LLC lifted its stake in shares of Eli Lilly and Company by 17.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 1,287 shares of the company’s stock valued at $994,000 after purchasing an additional 187 shares during the period. Coldstream Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 23,252 shares of the company’s stock valued at $17,951,000 after purchasing an additional 63 shares in the last quarter. Capital Analysts LLC raised its holdings in Eli Lilly and Company by 32.4% in the fourth quarter. Capital Analysts LLC now owns 3,557 shares of the company’s stock worth $2,746,000 after purchasing an additional 871 shares in the last quarter. Finally, Three Seasons Wealth LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $723,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LLY. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Morgan Stanley decreased their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a research note on Wednesday, April 9th. Guggenheim dropped their price target on Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Wells Fargo & Company boosted their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,017.00.

Eli Lilly and Company Stock Up 2.9 %

LLY opened at $884.94 on Friday. The stock has a market capitalization of $839.07 billion, a price-to-earnings ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. The firm has a 50 day moving average price of $827.69 and a 200-day moving average price of $818.61. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.